NPM1 and acute myeloid leukemia: DJ4 treatment was also active versus various AML patient-derived cells harboring mutations such as U2AF1, FLT3-ITD, HOXA9/NUP98, NPM1, KIT, and CBL (Figure 1 and Figure 2, Table 1 and Table S1).